-- Company broadens portfolio of regulatory information
management solutions to enhance client value
BOSTON, Feb. 19, 2014 /PRNewswire/ -- PAREXEL
International Corporation (NASDAQ: PRXL), a leading global
biopharmaceutical services provider, today announced the launch of
a new service line designed to provide a focused, market-driven
approach to regulatory outsourcing services in the life sciences
industry, with a primary emphasis on post-approval regulatory
activities.
Through PAREXEL Regulatory Outsourcing Services, the Company
will customize these services for clients based upon their unique
needs and business challenges by combining expertise, operational
approaches and technology. The service line will reside
within the PAREXEL Consulting business segment.
"With the ever-changing regulatory environment, pharmaceutical
companies face new challenges that need to be addressed with
efficiency and cost in mind," said Mark A.
Goldberg, M.D., President and Chief Operating Officer,
PAREXEL. "PAREXEL is uniquely positioned to provide this new
service offering, given our regulatory expertise, global
operational capabilities and information management technology.
Clients will now be able to outsource significant portions of their
regulatory activities to a trusted partner in a cost-effective
manner."
"Regulatory outsourcing is growing increasingly important in the
market as more and more companies rely on outsourcing to help them
with the complex task of managing their regulatory needs,
especially the regulatory maintenance of their marketed products,"
said Rick Riegel, Corporate Vice
President and new head of the PAREXEL Regulatory Outsourcing
Services line. "This service offering provides a unique solution
that addresses new pressures felt by our clients, allowing them to
become more efficient in the area of regulatory operations and
affairs."
The launch of PAREXEL Regulatory Outsourcing Services broadens
PAREXEL's portfolio of regulatory information management
solutions. In 2012, PAREXEL's acquisition of LIQUENT, Inc.
strengthened its regulatory capabilities by adding a robust
information technology platform, LIQUENT InSight®.
About PAREXEL International
PAREXEL
International Corporation is a leading global biopharmaceutical
services organization, providing a broad range of knowledge-based
contract research, consulting, medical communications, and
technology solutions and services to the worldwide pharmaceutical,
biotechnology and medical device industries. Committed to providing
solutions that expedite time-to-market and peak-market penetration,
PAREXEL has developed significant expertise across the development
and commercialization continuum, from drug development and
regulatory consulting to clinical pharmacology, clinical trials
management, medical education and reimbursement. PAREXEL
Informatics, Inc., a subsidiary of PAREXEL, provides advanced
technology solutions to facilitate the clinical development
process. Headquartered near Boston,
Massachusetts, PAREXEL operates in 76 locations in 50
countries around the world, and has 15,100 employees. For
more information about PAREXEL International, visit
www.PAREXEL.com.
PAREXEL, PAREXEL Informatics, LIQUENT, and HERON are registered
trademarks of PAREXEL International Corporation or its
affiliates.
This release contains "forward-looking" statements regarding
future results and events, including, without limitation,
statements regarding expected financial results, future growth and
customer demand. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed forward-looking statements. Without limiting the
foregoing, the words "believes," "anticipates," "plans," "expects,"
"intends," "appears," "estimates," "projects," "will," "would,"
"could," "should," "targets," and similar expressions are
also intended to identify forward-looking statements. The
forward-looking statements in this release involve a number of
risks and uncertainties. The Company's actual future results
may differ significantly from the results discussed in the
forward-looking statements contained in this release.
Important factors that might cause such a difference include, but
are not limited to, risks associated with: actual operating
performance; actual expense savings and other operating
improvements resulting from recent and anticipated restructurings;
the loss, modification, or delay of contracts which would, among
other things, adversely impact the Company's recognition of revenue
included in backlog; the Company's dependence on certain industries
and clients; the Company's ability to win new business, manage
growth and costs, and attract and retain employees; the Company's
ability to complete additional acquisitions, and to integrate newly
acquired businesses including the recent acquisitions of LIQUENT,
Inc. and HERON, Inc., or enter into new lines of business; the
impact on the Company's business of government regulation of the
drug, medical device and biotechnology industry;
consolidation within the pharmaceutical industry and competition
within the biopharmaceutical services industry; the potential for
significant liability to clients and third parties; the potential
adverse impact of health care reform; and the effects of exchange
rate fluctuations and other international economic, political, and
other risks. Such factors and others are discussed more
fully in the section entitled "Risk Factors" of the Company's
Quarterly Report on Form 10-Q for the fiscal quarter ended
December 31, 2013 as filed with the
SEC on January 31, 2014, which "Risk
Factors" discussion is incorporated by reference in this press
release. The Company specifically disclaims any obligation to
update these forward-looking statements in the future. These
forward-looking statements should not be relied upon as
representing the Company's estimates or views as of any date
subsequent to the date of this press release.
Contacts:
Diana Martin,
Vice President, Corporate Communications
PAREXEL International
Tel: +1-781-434-5516
Email: Diana.Martin@PAREXEL.com
Matthew Briggs
PAN Communications
Tel: +1-617-502-4300
Email: PAREXEL@pancomm.com